Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring

Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and multiple features such as TLS size, composition, and maturation status, when assessing their functional impact. With the aim of gaining insights into TLS biology and evaluating the prognostic impact of TLS maturity in Non-Small Cell Lung Carcinoma (NSCLC), we developed a multiplex immunofluorescent (mIF) panel including T cell (CD3, CD8), B cell (CD20), Follicular Dendritic cell (FDC) (CD21, CD23) and mature dendritic cell (DC-LAMP) markers. We deployed this panel across a cohort of primary tumor resections from NSCLC patients (N=406) and established a mIF image analysis workstream to specifically detect TLS structures and evaluate the density of each cell phenotype. We assessed the prognostic significance of TLS size, number, and composition, to develop a TLS scoring system representative of TLS biology within a tumor. TLS relative area, (total TLS area divided by the total tumor area), was the most prognostic TLS feature (C-index: 0.54, p = 0.04). CD21 positivity was a marker driving the favorable prognostic impact, where CD21<sup>+</sup> CD23<sup>-</sup> B cells (C-index: 0.57, p = 0.04) and CD21<sup>+</sup> CD23<sup>-</sup> FDC (C-index: 0.58, p = 0.01) were the only prognostic cell phenotypes in TLS. Combining the three most robust prognostic TLS features: TLS relative area, the density of B cells, and FDC CD21<sup>+</sup> CD23<sup>-</sup> we generated a TLS scoring system that demonstrated strong prognostic value in NSCLC when considering the effect of age, sex, histology, and smoking status. This TLS Score also demonstrated significant association with Immunoscore, EGFR mutational status and gene expression-based B-cell and TLS signature scores. It was not correlated with PD-L1 status in tumor cells or immune cells. In conclusion, we generated a prognostic TLS Score representative of the TLS heterogeneity and maturity undergoing within NSCLC tissues. This score could be used as a tool to explore how TLS presence and maturity impact the organization of the tumor microenvironment and support the discovery of spatial biomarker surrogates of TLS maturity, that could be used in the clinic.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2024-09-20
DOI
https://doi.org/10.3389/fimmu.2024.1422206
Citations
7
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.98
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring

Felix J. Segerer, Sophie E. Willis, Emma V. Jones, Julie Berthe et al.
7 citations
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
1.98
article

Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring

Felix J. Segerer, Sophie E. Willis, Emma V. Jones, Julie Berthe, Alma Andoni, Pawan Poudel, Miljenka Vuko, Tanja D. de Gruijl, Marco Testori, Felicia Ng, Rieneke van de Ven, Jorge Blando, Michael Surace, Jérôme Galon, Helen K. Angell, Megha Saraiya, Harald Hessel, Emily C. Jennings, Mari Heininen‐Brown
article en
7 citations

Abstract

Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and multiple features such as TLS size, composition, and maturation status, when assessing their functional impact. With the aim of gaining insights into TLS biology and evaluating the prognostic impact of TLS maturity in Non-Small Cell Lung Carcinoma (NSCLC), we developed a multiplex immunofluorescent (mIF) panel including T cell (CD3, CD8), B cell (CD20), Follicular Dendritic cell (FDC) (CD21, CD23) and mature dendritic cell (DC-LAMP) markers. We deployed this panel across a cohort of primary tumor resections from NSCLC patients (N=406) and established a mIF image analysis workstream to specifically detect TLS structures and evaluate the density of each cell phenotype. We assessed the prognostic significance of TLS size, number, and composition, to develop a TLS scoring system representative of TLS biology within a tumor. TLS relative area, (total TLS area divided by the total tumor area), was the most prognostic TLS feature (C-index: 0.54, p = 0.04). CD21 positivity was a marker driving the favorable prognostic impact, where CD21<sup>+</sup> CD23<sup>-</sup> B cells (C-index: 0.57, p = 0.04) and CD21<sup>+</sup> CD23<sup>-</sup> FDC (C-index: 0.58, p = 0.01) were the only prognostic cell phenotypes in TLS. Combining the three most robust prognostic TLS features: TLS relative area, the density of B cells, and FDC CD21<sup>+</sup> CD23<sup>-</sup> we generated a TLS scoring system that demonstrated strong prognostic value in NSCLC when considering the effect of age, sex, histology, and smoking status. This TLS Score also demonstrated significant association with Immunoscore, EGFR mutational status and gene expression-based B-cell and TLS signature scores. It was not correlated with PD-L1 status in tumor cells or immune cells. In conclusion, we generated a prognostic TLS Score representative of the TLS heterogeneity and maturity undergoing within NSCLC tissues. This score could be used as a tool to explore how TLS presence and maturity impact the organization of the tumor microenvironment and support the discovery of spatial biomarker surrogates of TLS maturity, that could be used in the clinic.

Frontiers in ImmunologyVol. 15
AstraZeneca (United Kingdom) (GB), Inserm (FR), Université Paris Cité (FR), Dutch Cancer Society (NL), Sorbonne Université (FR), AstraZeneca (South Korea) (KR), Centre de Recherche des Cordeliers (FR), La Ligue Contre le Cancer (FR), AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), AstraZeneca (Brazil) (BR), AstraZeneca (Japan) (JP), Laboratoire d’immunologie intégrative du cancer (FR), AstraZeneca (Finland) (FI), AstraZeneca (United States) (US), Amsterdam University Medical Centers (NL), AstraZeneca (Germany) (DE), Vrije Universiteit Amsterdam (NL)
Good health and well-being
Openalex Percentile: Top 11%
Cancer Immunotherapy and Biomarkers
1.98
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.